In an embodiment, the invention relates to compounds of Formula (I) and stereoisomeric forms thereof, wherein
R^1 is halo;
R^2 is hydrogen or halo;
R^3 and R^4 are hydrogen;
or R^3 and R^4 taken together form a bond;
R^5 is C_{1-4}alkylcarbonyl;
R^6 is hydrogen or halo;
and the pharmaceutically acceptable addition salts, and the solvates thereof.

In an embodiment, the invention relates to compounds of Formula (I) and stereoisomeric forms thereof, wherein
R^1 is halo; in particular chloro or fluoro; more in particular chloro;
R^2 is hydrogen or halo; in particular hydrogen, chloro ~~of~~ or fluoro;
R^3 and R^4 are hydrogen;
or R^3 and R^4 taken together form a bond;
R^5 is C_{1-4}alkylcarbonyl, C_{1-4}alkylsulphonyl, or C_{1-4}alkyl substituted with one hydroxyl moiety; in particular methylcarbonyl, methylsulphonyl or 1-hydroxyethyl;
R^6 is hydrogen or halo; in particular hydrogen or fluoro; more in particular hydrogen;
and the pharmaceutically acceptable addition salts, and the solvates thereof.

An embodiment of the present invention relates to those compounds of formula (I) or any subgroup thereof as mentioned in any of the other embodiments wherein R^1 is halo, C_{1-4}alkyl or C_{1-4}alkyloxy; and wherein R^2 is halo; in particular wherein R^1 and R^2 both are halo.

An embodiment of the present invention relates to those compounds of formula (I) or any subgroup thereof as mentioned in any of the other embodiments wherein at least one of R^1 and R^2 is other than hydrogen.

An embodiment of the present invention relates to those compounds of formula (I) or any subgroup thereof as mentioned in any of the other embodiments wherein R^1 is halo.

An embodiment of the present invention relates to those compounds of formula (I) or any subgroup thereof as mentioned in any of the other embodiments wherein R^2 is halo.

An embodiment of the present invention relates to those compounds of formula (I) or any subgroup thereof as mentioned in any of the other embodiments wherein R^3 and R^4 taken together form a bond.

In an embodiment, the invention relates to compounds of Formula (I-x) and (I-y) and stereoisomeric forms thereof, wherein

R^1 is halo; in particular chloro or fluoro; more in particular chloro;

R^2 is hydrogen or halo; in particular hydrogen, chloro ~~of~~ or fluoro;

R^3 and R^4 are hydrogen;

or R^3 and R^4 taken together form a bond;

R^5 is C_{1-4}alkylcarbonyl, C_{1-4}alkylsulphonyl, C_{1-4}alkylsulphinyl, or C_{1-4}alkyl substituted with one hydroxyl moiety; in particular R^5 is C_{1-4}alkylcarbonyl, C_{1-4}alkylsulphonyl, or C_{1-4}alkyl substituted with one hydroxyl moiety; more in particular methylcarbonyl, methylsulphonyl or 1-hydroxyethyl;

R^6 is hydrogen or halo; in particular hydrogen or fluoro; more in particular hydrogen;

and the pharmaceutically acceptable addition salts, and the solvates thereof.

In an embodiment, the invention relates to compounds of Formula (I-x) and stereoisomeric forms thereof, wherein

R^1 is halo; in particular chloro or fluoro; more in particular chloro;

R^2 is hydrogen or halo; in particular hydrogen, chloro ~~of~~ or fluoro;

R^3 and R^4 are hydrogen;

or R^3 and R^4 taken together form a bond;

R^5 is C_{1-4}alkylcarbonyl, C_{1-4}alkylsulphonyl, C_{1-4}alkylsulphinyl, or C_{1-4}alkyl substituted with one hydroxyl moiety; in particular R^5 is C_{1-4}alkylcarbonyl, C_{1-4}alkylsulphonyl, or C_{1-4}alkyl substituted with one hydroxyl moiety; more in particular methylcarbonyl, methylsulphonyl or 1-hydroxyethyl;

R^6 is hydrogen or halo; in particular hydrogen or fluoro; more in particular hydrogen;

and the pharmaceutically acceptable addition salts, and the solvates thereof.

In an embodiment, the invention relates to compounds of Formula (I-y) and stereoisomeric forms thereof, wherein

R^1 is halo; in particular chloro or fluoro; more in particular chloro;

R^2 is hydrogen or halo; in particular hydrogen, chloro ~~of~~ or fluoro;

R^3 and R^4 are hydrogen;

or R^3 and R^4 taken together form a bond;


R^5 is C_{1-4}alkylcarbonyl, C_{1-4}alkylsulphonyl, C_{1-4}alkylsulphinyl, or C_{1-4}alkyl substituted with one hydroxyl moiety; in particular R^5 is C_{1-4}alkylcarbonyl, C_{1-4}alkylsulphonyl, or C_{1-4}alkyl substituted with one hydroxyl moiety; more in particular methylcarbonyl, methylsulphonyl or 1-hydroxyethyl;

R^6 is hydrogen or halo; in particular hydrogen or fluoro; more in particular hydrogen;

and the pharmaceutically acceptable addition salts, and the solvates thereof.

Claims

1. A compound of formula (I)



(I)

or a stereoisomeric form thereof, wherein
R^1 is hydrogen, halo, C_{1-4}alkyl or C_{1-4}alkyloxy;
R^2 is hydrogen or halo;
R^3 and R^4 are hydrogen;
or R^3 and R^4 taken together form a bond;
R^5 is C_{1-4}alkylcarbonyl, C_{1-4}alkylsulphonyl, C_{1-4}alkylsulphinyl, or C_{1-4}alkyl substituted with one hydroxyl moiety;
R^6 is hydrogen or halo;
or a pharmaceutically acceptable addition salt or a solvate thereof.

2. The compound according to claim 1 wherein
R^1 is hydrogen, halo, C_{1-4}alkyl or C_{1-4}alkyloxy;
R^2 is hydrogen or halo;
R^3 and R^4 are hydrogen;
or R^3 and R^4 taken together form a bond;
R^5 is C_{1-4}alkylcarbonyl; C_{1-4}alkylsulphonyl; or C_{1-4}alkyl substituted with one hydroxyl moiety;
R^6 is hydrogen or halo;
or a pharmaceutically acceptable addition salt or a solvate thereof.

3. The compound according to claim 1 wherein
R^1 is chloro or fluoro;
R^2 is hydrogen, chloro ~~of~~ or fluoro;
R^5 is methylcarbonyl, methylsulphonyl or 1-hydroxyethyl;
R^6 is hydrogen or fluoro.

4. The compound according to claim 1 wherein
R^5 is C_{1-4}alkylcarbonyl.